PEPTIDE CORTEXThe library
← The library

Cerebrolysin

region-specificCognition/Mood
Evidence grade
BRegion-specific approval (not US FDA)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeNeurotrophic support
MechanismMixture of neuropeptides used in some countries
EffectsMixture of neuropeptides used in some countries
DosingNo human dose established.
Bottom lineUsed clinically in some countries; not standard in the US—specialist oversight.
Protocols · as published2 sourced
Clinical trialCARS post-stroke trial (Muresanu, Stroke 2016)
RouteIntravenous infusion
FrequencyOnce daily, 21 days
Starting30 mL IV once daily, starting 24-72 h after stroke onset
EscalationNone
Target30 mL IV once daily for 21 days plus standardised rehabilitation

Clinical doses are mL of a porcine brain peptide preparation. Approved in about 50 countries, not by the FDA.

Community protocol — not clinically establishedCommunity guide — research-vial pattern
RouteSubcutaneous or intramuscular (research vials)
FrequencyDaily
Starting20 mg/day, week 1
Escalation24 mg week 2; 28 mg week 3
Target32 mg/day, week 4+

A different product at a different scale from the clinical mL doses — about 1/200th of a clinical daily dose.

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved in US; adverse effects possible; clinician use

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.